BrightGene Bio-Medical Technology Balance Sheet Health
Financial Health criteria checks 3/6
BrightGene Bio-Medical Technology has a total shareholder equity of CN¥2.4B and total debt of CN¥2.2B, which brings its debt-to-equity ratio to 88.2%. Its total assets and total liabilities are CN¥5.0B and CN¥2.5B respectively. BrightGene Bio-Medical Technology's EBIT is CN¥193.4M making its interest coverage ratio 4.8. It has cash and short-term investments of CN¥1.0B.
Key information
88.2%
Debt to equity ratio
CN¥2.15b
Debt
Interest coverage ratio | 4.8x |
Cash | CN¥1.02b |
Equity | CN¥2.44b |
Total liabilities | CN¥2.53b |
Total assets | CN¥4.97b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 688166's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥858.9M).
Long Term Liabilities: 688166's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥1.7B).
Debt to Equity History and Analysis
Debt Level: 688166's net debt to equity ratio (46.5%) is considered high.
Reducing Debt: 688166's debt to equity ratio has increased from 0% to 88.2% over the past 5 years.
Debt Coverage: 688166's debt is not well covered by operating cash flow (9.5%).
Interest Coverage: 688166's interest payments on its debt are well covered by EBIT (4.8x coverage).